Brief: Lipocine Inc - On Oct. 2, 2023, Co Received Notice From Antares Of Antares' Termination Of License Agreement
Oct 6 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC - ON OCTOBER 2, 2023, COMPANY RECEIVED NOTICE
FROM
ANTARES OF ANTARES' TERMINATION OF LICENSE AGREEMENT
* LIPOCINE INC - IN ACCORDANCE WITH TERMS OF LICENSE
AGREEMENT,
LICENSE AGREEMENT WILL TERMINATE EFFECTIVE JANUARY 31, 2024
* LIPOCINE INC - CURRENTLY PLANS TO SEEK A COMMERCIALIZATION
PARTNER FOR TLANDO
Further company coverage: LPCN.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy